Armatus Bio
CompanyUnited States
Armatus Bio develops 2 assets, the furthest preclinical (ARM-201 in facioscapulohumeral muscular dystrophy). Mostly gene therapy acting on PMP22; based in the United States.
- 2
- Assets
- Furthest stage
- Preclinical
- 1
- Grant
- 0
- Trials
- 0
- Signals
Pipeline
2Vectorized engineered microRNA regulates gene expression through RNA interference.
Preclinical, Gene therapy, facioscapulohumeral muscular dystrophy
AAV9-delivered microRNA silences PMP22 to reduce protein overproduction and restore myelin structure and motor function.
Preclinical, Gene therapy, PMP22, charcot-marie-tooth disease type 1A
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- People8
- Similar companies5